Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy
Version of Record online: 6 APR 2004
Volume 59, Issue 5, pages 491–497, May 2004
How to Cite
Tonnel, A. B., Scherpereel, A., Douay, B., Mellin, B., Leprince, D., Goldstein, N., Delecluse, P. and Andre, C. (2004), Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy, 59: 491–497. doi: 10.1111/j.1398-9995.2004.00456.x
- Issue online: 6 APR 2004
- Version of Record online: 6 APR 2004
- Accepted for publication 3 November 2003
- allergen-specific immunotherapy;
Background: The efficacy and safety of sublingual immunotherapy (SLIT) in patients with chronic rhinitis related to sensitization to house dust mites are still controversial.
Methods: After application of an anti-mite mattress cover, patients were only included in the study when the cumulative symptom score over a fortnight was greater than 70 out of a possible total of 168. Thirty-two of the 120 patients selected were randomized to receive SLIT for 2 years: 17 received placebo and 15 received the Dermatophagoides pteronyssinus and D. farinae 50/50 allergen extract.
Results: Significant between-group differences were observed after 1 year and persisted at the end of the second year for the rhinitis total score (P < 0.02), blocked nose score (P < 0.01) and nasal itching score (P < 0.01). Skin reactivity to house dust mites was significantly reduced in the group receiving house dust mite extract (P < 0.03). No statistical difference was observed between the two groups for medication scores, but a low medication consumption was observed in all patients. No serious and no systemic adverse reactions were reported.
Conclusion: This study indicates the superiority of active treatment vs. placebo, evaluated on efficacy criteria (rhinitis score) or objective criteria (skin reactivity). The availability of a solid form (tablet) could represent a progress in terms of patient acceptability.